Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
555 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Population Pharmacokinetic Modeling for the Iminosugar Lucerastat Supports Dose Adaptation in Patients With Fabry Disease and Moderate to Severe Renal Function Impairment.
Brussee JM, Dingemanse J, Lott D, Berger B, Frey A, Krause A. · J Clin Pharmacol · 2026 · cited 0 timesclinical trial, phase iii, clinical trial, phase i
- Prevalence of Fabry disease in cryptogenic stroke: a systematic review and meta-analysis with meta-regression.
Magalhães PLM, Gonçalves OR, Meira OT, da Silva AMP, de Maximiano MLB, Han ML, Falcão L, de Farias EH, Carretta LTA, Malfetano FR. · J Neurol · 2025 · cited 1 timesmeta-analysis, systematic review
- Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Moolenaar LR, Ali M, Aufenacker TJ, Beets GL, Bosker RJI, Buffart TE, Burger JW, Dekker E, Denost Q, Doornebosch PG, Duijvendijk PV, Fabry HFJ, Geijsen ED, Gerhards MF, van Grevenstein WMU, Grotenhuis BA, Hoff C, Leijtens JWA, Peeters KCMJ, Pronk A, van der Schelling GP, Sietses C, Smits AB, Toorenvliet BR, van de Ven AWH, Verdaasdonk EGG, Vuylsteke RJCLM, van Westreenen HL, de Wilt JHW, Zimmerman DDE, Lange MM, van Grieken NCT, Bastiaansen BAJ, Hompes R, Marijnen CA, Dijkgraaf MGW, Moons LMG, Tanis PJ, Cunningham C, Tuynman JB, TESAR Study Group. · Lancet Gastroenterol Hepatol · 2026 · cited 2 timesclinical trial, phase iii, comparative study
- Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.
Nordbeck P, Goker-Alpan O, Bernat JA, Germain DP, Giraldo P, Jovanovic A, Kimonis V, Nicholls K, Rockman-Greenberg C, Schiffmann R, Thomas M, Tylki-Szymanska A, Wallace E, Welford RWD, West ML, Clozel M, Frey A, Trokan L, Mueller MS, Vogler M, Wanner C, Hughes D. · Nat Commun · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease.
Germain DP, DasMahapatra P, Liu S, Deegan P, Ortiz A, Modur V, Wilcox WR. · Mol Genet Genomic Med · 2025 · cited 3 timesOpen accessclinical trial, phase iii, clinical trial, phase ii
- Long-term efficacy of migalastat in females with Fabry disease.
Kallish S, Camporeale A, Hopkin RJ, Jovanovic A, Nordbeck P, Veleva-Rotse BO, Krusinska E, Torra R. · J Med Genet · 2025 · cited 5 timesOpen accessclinical trial, phase iii, multicenter study
- Detection and treatment of peritoneal metastases in colon cancer: COLOPEC trial compared to routine practice.
Hochstenbach I, Hamm JJM, Rademaker E, Aalbers AGJ, Boerma D, van Grevenstein WMU, Hemmer PHJ, De Hingh IHJT, Kok NFM, Tuynman JB, Madsen EVE, de Wilt JHW, Consten ECJ, van Westreenen HL, Tanis PJ, COLOPEC Collaborators Group, Dutch Snapshot Research Group and Dutch Complex Colon Cancer Initiative. · Colorectal Dis · 2026 · cited 0 timesOpen accesscomparative study, multicenter study
- Cost-effectiveness of the gluteal turnover flap for perineal wound closure after abdominoperineal resection: randomized clinical trial.
van den Berg R, Musters GD, Verhoef C, Blommestein HM, Tanis PJ, BIOPEX-2 Study Group. · BJS Open · 2026 · cited 0 timesOpen accessmulticenter study, randomized controlled trial
- A Meta-Analysis to Unveil the Diagnostic Gaps in Anderson-Fabry Disease in Women.
Lenzini L, Pintus G, Gugelmo G, Burlina AP, Fadini GP, Burlina AB, Vitturi N. · J Inherit Metab Dis · 2026 · cited 1 timesOpen accessmeta-analysis, review
- Impact of enzyme replacement therapy on hearing sensitivity in Fabry disease: A systematic review.
Konadath S, Prakash P, Abraham A, Sanitha AS, Krishna Y, Almudhi A, Madathodiyil I, Hussain RO. · Eur Arch Otorhinolaryngol · 2026 · cited 0 timessystematic review
- Evaluating the relationship between antidrug antibodies and efficacy and safety outcomes in patients with Fabry disease receiving enzyme replacement therapy: a systematic literature review.
Aguiar P, Bernat JA, Hughes D. · Orphanet J Rare Dis · 2026 · cited 0 timesOpen accessresearch support, non-u.s. gov't, systematic review
- Global prevalence of nocturnal hypertension: systematic review and meta-analysis.
Show KL, Lim ZY, Teong CCY, Sng EHY, Lee EK, Moosa AS, Ng CJ. · BMC Public Health · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Diagnosis, treatment, and follow-up of Fabry disease in pediatrics.
Cárdenas-Aguilera JG, Chacón-Acevedo KR, Zarante-Bahamón AM, Serrano-Gayubo AK, Prieto-Rivera JC, Meza-Martínez AI, Rojas-Martínez JA, Cáceres-Mosquera JA, Duarte-Amorocho ML, Pérez-Alfonso CM, Jiménez-Triana CA, Baquero-Rodríguez R, Flórez-Rodríguez CX, Reina-Ávila MF, Guerrero-Tinoco GA, Guarnizo-Zuccardi P, Sánchez-Gómez J, Vélez-Echeverry C, Rubio-Elorza LM, Del Roció Mera-Solarte P, Carrascal-Guzmán MI, Baena PSA, Rozo-Agudelo N, Olivas-Valdez MA, Trimarchi-Jurado H, Canal-Delgado I, Marques-Lourenço C, Reyes-Morales L, Belmont-Martínez L, Cabrera GH, Politei JM, Pintos-Morell G, Ripeau DB, Perretta FJ. · Mol Genet Metab · 2026 · cited 2 timessystematic review
- Unraveling the Hidden Burden of Gastrointestinal and Nutritional Challenges in Children with Fabry Disease: A Systematic Review with Meta-Analysis.
Dargenio VN, Natale M, Castellaneta SP, Grasta G, Paulucci L, Dargenio C, Francavilla R, Cristofori F. · Nutrients · 2025 · cited 4 timesOpen accessmeta-analysis, systematic review
- Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.
Holida M, Linhart A, Longo N, Wallace E, Tøndel C, Hughes D, Warnock DG, Pisani A, Eyskens F, Deegan P, Feldt-Rasmussen U, Goker-Alpan O, Mehta A, Piotti G, Fichera V, Wang M, Chertkoff R, Waldek S, Wilcox WR, Bernat JA. · Orphanet J Rare Dis · 2026 · cited 0 timesOpen accessclinical trial, phase iii, multicenter study
- The efficacy of BLS training among fifth-year medical students-a randomized, assessor-blinded, parallel group trial.
Fritúz G, Kovács G, Kállai A, Nagy T, Maár C, Szvath P, Berczi M, Fábry S, Skultéti D, Iványi Z, Gál J, Kovács E. · BMC Med Educ · 2026 · cited 0 timesOpen accessrandomized controlled trial
- Fabry disease cardiomyopathy: A state-of-the-art review.
Pande S, Varzideh F, Gambardella J, Jankauskas SS, Cerasuolo FA, Spinelli L, Kansakar U, De Luca A, Kurland IJ, Sidoli S, Iaccarino G, Sadoshima J, Santulli G. · Prog Cardiovasc Dis · 2025 · cited 17 timesOpen accesssystematic review
- Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal metastases: individual patient data meta-analysis.
Hamm JJM, van den Berg R, Andrinopoulou ER, Zwanenburg ES, Musters GD, Tanis PJ, Arjona-Sanchez A, COLOPEC and HIPECT4 Collaborator Groups. · Br J Surg · 2025 · cited 8 timesOpen accessmeta-analysis, systematic review
- Imaging predictors of adverse prognosis in Fabry disease cardiomyopathy: A systematic review and meta-analysis.
Stankowski K, Figliozzi S, Rojanathagoon T, Bampatsias D, Klettas D, Monti L, Bragato R, Masci PG, Francone M, Condorelli G, Imbriaco M, Pieroni M, Camporeale A, Georgiopoulos G. · Eur J Clin Invest · 2025 · cited 8 timesOpen accessmeta-analysis, systematic review
- IgM nephropathy is a controversial entity: a distinct nephropathy or part of the podocytopathy spectrum? A systematic review of the literature.
Ozcan SG, Ersoy Y, Karalı O, Murt A, Dincer MT, Trabulus S, Seyahi N. · BMC Nephrol · 2026 · cited 0 timesOpen accesssystematic review
- Effectiveness of Family Interventions in Bipolar Disorder: A Systematic Review.
Umer M, Burgos M LA, Syed N, Xu C, Rodak T, Dennis CL, Naeem F, Mulsant B, Husain MI. · Bipolar Disord · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design.
Quintana-Hayashi MP, Connolly K, Millegård M, Bhattacharya C, Åstrand M, Turton M, Pizzato PE, Januzzi JL, Rosenmeier JB. · ESC Heart Fail · 2026 · cited 2 timesOpen accessclinical trial, phase ii, multicenter study
- Effects of Enzyme Replacement Therapy on Cardiac MRI Findings in Fabry Disease: A Systematic Review and Meta-Analysis.
Figliozzi S, Kollia E, Simistiras A, Camporeale A, Stankowski K, Masci PG, Mavraganis G, Lombardi M, Condorelli G, Francone M, Pieroni M, Georgiopoulos G. · Radiol Cardiothorac Imaging · 2024 · cited 12 timesmeta-analysis, systematic review
- Kidney Function and Blood and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Related Dementias: Systematic Review and Meta-Analysis.
Lin Y, Zhao Z, Zhu N, Garcia Ptacek S, Carrero JJ, Bruchfeld A, Eriksdotter M, Mielke MM, Brusselaers N, Brusselaers N, Xu H. · J Am Soc Nephrol · 2026 · cited 6 timesOpen accessmeta-analysis, systematic review
- Transcriptomic Approach in Understanding Fabry Nephropathy: A Review of the Literature and Proof-of-Concept.
Breznik N, Levstek T, Vujkovac B, Cokan Vujkovac A, Trebušak Podkrajšek K. · Genes (Basel) · 2025 · cited 3 timesOpen accesssystematic review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.